Popular, Mergers, Pharmaceutical Industry

Healthcare Trends & Transactions Q2 2025

Bass, Berry & Sims PLC on 7/30/2025

The healthcare mergers and acquisitions (M&A) market remained active in Q2 2025, with several sectors including physician practice management (PPM), clinical research, and digital health experiencing continued investment and...more

Healthy returns: European life sciences M&A heats up as sector faces demographic reckoning

White & Case LLP on 7/23/2025

Dealmaking in Europe’s life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength as companies respond to the stark realities of an aging population - Earlier this...more

Healthcare Trends & Transactions Q1 2025

Bass, Berry & Sims PLC on 4/17/2025

The healthcare mergers and acquisitions (M&A) market began 2025 with a slower start than expected given the easing headwinds and building momentum at the end of last year, with the number of deals reported in Q1 lower than...more

Sights and Sounds from the Antitrust Section’s 2025 Spring Meeting

Morrison & Foerster LLP on 4/9/2025

Antitrust experts from across the globe convened in Washington, D.C. on April 2–4, 2025 to discuss new enforcement policies and share updates on current issues in antitrust. We provide the key highlights from numerous panels...more

Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025

Ropes & Gray LLP on 2/28/2025

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw a resurgence, signaling renewed investor confidence and reflecting sustained...more

Antitrust and Competition Life Sciences Year in Review 2024

Goodwin on 2/21/2025

The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission (FTC) in the life sciences space, continuing a yearslong pattern of close...more

The Fate of the “Last Gasp” of the Biden FTC: Will Its Legacy Survive the Trump Administration?

Axinn, Veltrop & Harkrider LLP on 1/27/2025

In the days leading up to President Trump’s inauguration, the Biden FTC rushed to initiate major lawsuits and to tie a bow on various antitrust policy efforts. In a series of dissenting statements, the minority Republican...more

IP, Licensing, and M&A in the Life Sciences Industry: Trends to Watch in 2025

Morgan Lewis - As Prescribed on 1/20/2025

The life sciences industry has long been at the forefront of innovation, and 2025 promises to continue this trajectory with exciting developments in intellectual property (IP), licensing, and mergers and acquisitions (M&A)....more

Life Sciences M&A Trends for 2023 and 2024 (Through End of Q3) in Greater China

Goodwin on 11/11/2024

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s life sciences sector. ...more

Antitrust and Competition Life Sciences Quarterly Update Q2 2024

Goodwin on 9/10/2024

To date, 2024 has not yet seen the type of mega-merger (Pfizer/Seagen) or level of agency enforcement (Sanofi/Maze or Amgen/Horizon) as 2023. But two notable investigations — one still active — show the Federal Trade...more

European Antitrust Bimonthly Bulletin – July/August 2024

Wilson Sonsini Goodrich & Rosati on 9/6/2024

The "European Antitrust Bimonthly Bulletin” breaks down the major antitrust developments in Europe during the past two months into concise and actionable takeaways. ...more

Healthcare Experts See Promising Signs of Rebound in M&A and IPO Activity

Goodwin on 2/28/2024

In the second week of January, Goodwin and KPMG convened innovators, practitioners, regulators, and others for our annual symposium on the future of life sciences and healthcare. This marked the fifth year that Goodwin...more

The European Commission report on competition enforcement in the pharmaceutical sector

Hogan Lovells on 2/2/2024

On 26 January 2024, the European Commission published a report on competition enforcement in the pharmaceutical sector, highlighting the role of EU competition law in safeguarding market participants and consumers,...more

2024 Healthcare Private Equity Outlook & Trends

Bass, Berry & Sims PLC on 1/9/2024

W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity. As we begin 2024, we have highlighted the issues and trends that...more

Healthcare Trends & Transactions Q3 2023

Bass, Berry & Sims PLC on 11/10/2023

After steadying during Q2, it appears the overall volume of deals in the healthcare industry declined in Q3 compared with Q2, and year-to-date 2023 is still down from last year. A slumping economy has no doubt played a large...more

Antitrust & Competition Life Sciences Quarterly Update - Q3 2023

Goodwin on 10/24/2023

The FTC’s Amgen/Horizon Lawsuit Ends With a Whimper - We covered the FTC’s investigation into (and litigation challenging) Amgen’s $28.3 billion acquisition of rare disease specialist Horizon Therapeutics in our Q1 and...more

Transatlantic M&A bull run set for comeback

White & Case LLP on 9/15/2023

Encouraged by the relative strength of the dollar and improving financing conditions, US bidders are snapping up European assets - Transatlantic M&A was enjoying record-high activity before the war in Ukraine sparked...more

Healthcare Trends & Transactions Q2 2023

Bass, Berry & Sims PLC on 7/28/2023

The healthcare M&A market appears to be steadying. Although deal activity through the year appears slightly below the high-water marks for the corresponding period of 2022, deal activity is generally up from the first quarter...more

Inside the Courts – An Update From Skadden Securities Litigators - May 2023

Skadden, Arps, Slate, Meagher & Flom LLP on 6/1/2023

Supreme Court Hears Argument on Traceability Requirement in Circuit-Split Slack v. Pirani - Key Points - - Before the end of June, the U.S. Supreme Court is expected to issue a decision in a high-profile securities case...more

Antitrust & Competition Life Sciences Quarterly Update - Q1 2023

Goodwin on 5/25/2023

Our prior updates covered how FTC enforcement activity largely proceeded “as usual” during 2022 in the life sciences industry, with large pharmaceutical players buying or licensing promising, but still risky, assets from...more

Antitrust & Competition Life Sciences 2022 Year In Review

Goodwin on 2/22/2023

M&A activity in the life sciences space proceeded largely as usual in 2022, with most transactions receiving expected levels of agency scrutiny and closing in the normal course despite aggressive rhetoric from new leadership...more

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley LLP on 1/26/2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020), life sciences deal flow in 2022 on balance remained strong despite...more

Global healthcare M&A delivers strong performance

White & Case LLP on 1/25/2023

Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more

Antitrust & Competition Life Sciences Quarterly Update - Q3 2022

Goodwin on 11/10/2022

The third quarter in the life sciences space showed that business is generally proceeding as usual, with large pharma players successfully acquiring or licensing in clinical stage assets without running into antitrust delays....more

Healthcare Transactions Q1 2022

Bass, Berry & Sims PLC on 4/15/2022

2022 started strong for healthcare transactions with some reports suggesting a record-breaking January. Although deal activity cooled in February and March, transaction pipelines still indicate that 2022 is on pace to match...more

Today's Popular Updates › Mergers › Pharmaceutical Industry

"My best business intelligence, in one easy email…"